PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
http://www.peervoice.com
Asked and Answered: Differentiating Between PARP Inhibitors in First-Line Advanced Ovarian Cancer
Visit https://www.peervoice.com/SSK860 to view the entire programme with slides. After completing “Asked and Answered: Differentiating Between PARP Inhibitors in First-Line Advanced Ovarian Cancer”, participants will be able to: Describe the importance of first-line maintenance therapy for patients with advanced ovarian cancer: Differentiate among PARP inhibitors in terms of mutation status, dosing and administration, and adverse events; Formulate optimal personalised treatment plans taking into account individual- and disease-related factors for patients with advanced ovarian cancer.